In 2023 the FDA published guidance on rare diseases. The guidance recognises that many rare diseases are serious conditions ...

This approach, while embedded in clinical guidelines and workflow protocols, does not reflect the underlying biology of ...

At this year's American Society of Clinical Oncology’s Annual Meeting, AstraZeneca presented late-breaking data from the DESTINY-Breast09 Phase III trial evaluating first-line treatment in patients ...

Bayer's rivalry with Boehringer Ingelheim in the development of medicines for HER2-mutated non-small cell lung cancer (NSCLC) ...

That's the top-line finding of the latest financing report from the UK BioIndustry Association (BIA), which reveals that ...

Roche has added another phase 3 trial in its programme for Alzheimer's disease candidate trontinemab and will now test the ...

GSK has moved to shore up its R&D pipeline with a strategic-level deal with China's Jiangsu Hengrui Pharma that spans a dozen drug candidates and could be worth up to $12.5 billion.

Owkin has enticed another big pharma partner with its artificial intelligence-powered clinical development platform, Bristol-Myers Squibb, which is paying $80 million upfront to tap into its ...

A vaccine for Alzheimer’s disease developed by United Neuroscience has cleared a phase IIa trial, and seems to be free of the toxicity that has scuppered earlier candidates. To be clear, there ...

UK digital health company Sensyne Health has launched a new smartphone app to help people across the diabetes spectrum manage their condition. The app – called DBm-Health – can help users to ...

Robin Walsh takes a look back at the origins of the industry in the 19th century and its ongoing evolution ...

Innovent prepares to file GLP-1/glucagon agonist mazdutide in China for diabetes, its second indication after obesity.